View Article

  • Formulation And Evaluation of Anthralin Nano Particle Loaded Shampoo for Alopecia Areata

  • 1Research Scholar, Shri JJT University, Rajasthan. 
    2Department of Pharmaceutical Sciences, Shri JJT University Rajasthan
    3Department of Pharmaceutical Chemistry, Dr. Moopen’s College of Pharmacy, Wayanad, Kerala.

Abstract

The physical, mental and social dimensions of life are negatively affected by alopecia areata and can be greater than those resulting from life-threatening disease like myocardial infarction. Therapeutic concentration of anthralin should reach to deeper epidermal regions to exert effect on mitochondrial function and structure but most of conventional creams fail to do so. Method at laboratory scale: Chitosan nanoparticle prepared by melt emulsification. This method is fast, feasible in laboratory scale; avoid use of organic solvent and highly reproducible. A combination of surfactants had been taken to offer electrostatic repulsion and steric stabilization which is necessary to maintain physical stability of chitosan nanoparticle. NLC formulation had higher drug retention in comparison to chitosan nanoparticle after storage up to 06 months due to its amorphous nature. Recent formulation development initiatives including our investigation have validated utility of chitosan nanoparticle in topical drug delivery at least in case of anthralin.

Keywords

Alopecia Areata, Anthralin, chitosan nanoparticle, shampoo, Melt emulsification, surfactants, zeta potential

Introduction

The history of diseases dates back to ancient civilizations, with natural remedies used to treat various            malfunctions. Scientific progress has led to the recognition and separation of active compounds in raw materials, their modes of action, and their chemical processes for lab-based synthesis. Drug delivery aims to transport the medicament to the target site at an adequate concentration for an adequate duration. Carrier systems have been continuously developed since their inception in the early 20th century to ensure that medicaments are delivered to the targeted site of action with regulated release. Development in polymer technology and nanotechnology led to the development of biodegradable and biocompatible polymers and a reduction in size or miniaturization techniques to see the path for drugs and their carrier system at the colloidal level. Nanotechnology has significantly transformed the strategies and emphasis of research and applications regarding disease diagnosis, treatment, monitoring, and management.

1.1 Nano Particle6-8

The term "nanoparticle" in pharmaceutics implies structures less than 1μm in diameter.
Nanoparticles are particles having size range under 100 nm. These materials have significant roles in contemporary medicine in recent years, with uses varying from contrast agents in medical imaging to carriers for delivering genes to specific cells. The benefits of nanoparticles in modern medicine are numerous. Colloidal/Particulate system, developed through the colloidal method, offers potential for drug delivery in pharmaceutical-healthcare systems.The system includes lipid nanoparticles, liposomes, nanosomes, conjugates, nanoconjugates, nanocrystals, drugs, implants, nano constructs, nano emulsion, and nanosuspension.

    1. Shampoo9

Shampoo is a hair care product used to get rid of contaminants such oils, grime, dandruff, skin cells, and other skin and skin-related debris that slowly accumulate in hair. The concentration of shampoo is around 8% because it must be gentle on the skin and cause less discomfort to the eyes. Alcohol ether sulphates and salts like sodium are frequently employed as surfactants in shampoo.

1.3 Anthralin10-13

Anthralin, a hydoxanthrones, is used for treating alopecia by causing redness or irritation of the scalp due to free radicals. It is applied as short-contact therapy, causing itching, redness, scaling, and staining of skin, hair, and clothes. Unstable anthralin is oxidized to anthralin dimmer, which is insoluble and eliminated in urine. Oxidized products cause violet-brown staining of cloths and skin, and do not possess hair regrowth activity.  It is also known as Anthralin, Dihydroxyanthranol, Anthranol and 1,8 – Dihydroxy 9Anthrone, Anthralinum (Latin), Anthralin (German), Anthralin (French), Ditranol (Spanish). It is an yellow or orange-yellow, fine crystalline, odourless or almost odorless powder. It is soluble in chloroform and oils, slightly soluble in ethanol (95%). Its absorption is more in skin with impaired stratum corneum barrier in 30 minutes, about 16 hours into intact skin. Its metabolism is oxidized to dianthrone, insoluble polymerization products. It is used for various psoriatic conditions and Alopecia areata. Its toxicity and side effects are directly proportional to the amount of drug product being used.

  1. MATERIALS AND METHODS

Materials used in this work were procured from different manufactures and used without purification. All chemicals and solvents used was of analytical grade. Formulation components were examined on physicochemical ground. Pre-formulation studies were designed to fix optimum conditions for a stable formulation such as physical appearance, solubility analysis, melting point determination.14-16

2.1 Preparation of Nanoparticle Loaded Shampoo

The nanoparticles were prepared by spontaneous emulsification method at various ratio of chitosan, oil and drug as mentioned in the table 4.3. The drug was dissolved in glacial acetic acid and kept aside. Then dissolve chitosan in glacial acetic acid and stirred for 2 hours and kept overnight. After the dissolution of chitosan, the drug was added into it by continuous stirring for 2 hours. Further the mixture of drug and chitosan nanoparticle were added drop by drop into oil phase to get a emulsion. The mixture was stirred continuously for 1 hour. Then glutaraldehyde was added into it and stirred for 2 hours. Add EDTA and ascorbic acid and stirred for 2 hours. Finally, the nanoparticle was collected by centrifugation at 10000rpm for 1 hour and dried nanoparticle were kept in desiccator.17-19

Table 1.1 Formulation of drug loaded nanoparticle

Sl No

Formulation Code

Drug: Chitosan

1

F1

1:1

2

F2

1:1.5

3

F3

1:2

4

F4

1:2.5

Table no. 1.2 Ingredients and their composition of shampoo

Sl No

Ingredient

Quantity (g)

1

Sodium Lauryl Sulphate

2

2

Sodium Sulphate

0.5

3

Sodium Chloride

0.1

4

Water

10L

5

Sodium CMC

0.25

6

Span 80

0.1L

7

Triethanolamide

0.5

8

Stearic acid

0.5

9

Polyethelyene Glycol

0.5

10

Citric Acid

0.2

11

Methyl Paraben

0.01

12

Glycerine

0.5L

2.2 Evaluation of nano shampoo20

  • Organoleptic properties: The colour of shampoo was visually examined against black and white background. The odour of the shampoo was also analysed.
  • pH Measurement: Dissolved 5ml of shampoo in 100ml distilled water and then measured the pH meter.
  • Viscosity: A Brookfield viscometer RV series model was used to calculate the viscosity of the produced mixtures. At 25°C, the viscosity of the chosen formulations was measured by pouring them into the viscometer's sample adaptor. The viscosity was tested five minutes following the spindle's rotation using spindle number 3 and 4 at a speed of ten revolutions per minute.
  • Drug Content Determination: The drug content was determined using UV Spectrophotometer. 0.5g of nanoparticle was diluted with 10ml chloroform followed by continuous shaking until a clear solution and it is filtered with 0.45micron filter paper, from the filtered solution 5ml is taken and diluted to 10ml. Drug concentration in the solution was determined by UV Spectrophotometer at 254nm using formula [70]:

Drug Loading/ Encapsulation Efficiency: A small portion of Nano dispersion centrifuged at 10000rpm for 1 hour the supernatant was removed amount of unincorporated drug was measured by taking the absorbance of appropriately diluted supernatant solution at 254nm using VU Spectrophotometer, drug loading efficiency calculated using equation:

  1. RESULTS AND DISCUSSION

Analysis of Drug

Table 1.3 Physical appearance of drug

SI No.

Solvent

Observation

1

Colour

Yellow to red powder

2

Odour

Odourless

3

Nature of powder

Amorphous powder

Table 1.4 Solubility of Dithranol

SI No.

Solvent

Observation

1

Water

Insoluble

2

Glacial acetic acid

Slightly Soluble

3

Chloroform

Soluble

4

Benzene

Soluble

5

Acetone

Soluble

6

Ethanol

Slightly soluble

7

Phosphate Buffer

Insoluble

Melting Point

Table 1.5 Melting point of dianthrol

Drug

Observed Value of Melting Point

Reported Value

Drug

Dithranol

178oC

178oC

Dithranol

Determination of λmax: The absorbance maxima of drug were found using AN-UV7000 UV-Visible spectroscopy and the maximum absorbance of the drug was found at 254nm,284nm, and 354 nm.

Figure 1.1 Absorbance maxima of dithranol

Preparation of Standard Curve: The calibration curve of dithranol was performed using AN-UV7000 UV-Visible spectroscopy and the absorbance at various concentration (10,20,30,40,50µg/ml) was taken and regression was found to be 0.9972.

Table 1.6 Standard plot of dithranol

Sl.No

Concentration

Absorbance

1

0

0

2

10

0.245

3

20

0.456

4

30

0.635

5

40

0.844

6

50

1.033

Figure 1.2 Calibration curve of dithranol

HPLC: The HPLC was performed by using CBM-20ALITE Column 8 reverse phase at 254nm. 20μL of Dithranol was injected to the HPLC and the retention time and the area was found to be 5.403 and 5345.112 respectively.

Figure No. 1.3 HPLC of Dithranol

Evaluation of Nano Shampoo

pH: The pH of the F1, F2, F3, F4 was performed using MKVI,19370 MODEL pH meter and concluded that the F3 formulation shows the similar pH range of psoriatic skin. Hence F3 formulation is considered to be best for the psoriatic skin.

Table 1.7 pH of Dithranol Nano shampoo using different formulation

Sl. No

Formulation

pH

1

F1

5.48

2

F2

5.6

3

F3

4.88

4

F4

5.9

Viscosity: The Viscosity was performed for F1, F2, F3 and F4 formulation using Ostwald Viscometer and concluded that the formulations show good flow property which are needed for the shampoo.

Table 1.8 Viscosity of dithranol Nanoshampoo using different formulation

Sl. No

Formulation

Viscosity

1

F1

0.00123

2

F2

0.00118

3

F3

0.00102

4

F4

0.00112

Drug Content Determination: The drug content determination was performed on various formulation using AN-UV7000 UV-Visible spectroscopy and the best drug content was found in the F3 formulation.

Table 1.9 Drug Content Determination of Dithranol Nanoshampoo using different formulation

Sl. No

Formulation

Viscosity

1

F1

0.00123

2

F2

0.00118

3

F3

0.00102

4

F4

0.00112

Drug Content Determination: The drug content determination was performed on various formulation using AN-UV7000 UV-Visible spectroscopy and the best drug content was found in the F3 formulation.

Table 1.9 Drug Content Determination of Dithranol Nanoshampoo using different formulation

Sl. No

Formulation

Drug Content

1

F1

76.13%

2

F2

80.26%

3

F3

84.5%

4

F4

79.32%

Drug Loading/ Encapsulation Efficiency: AN-UV7000 UV-Visible spectroscopy was used to perform drug loading efficacy of polymer (chitosan). The best encapsulation efficiency of chitosan: drug was found to be 2:1 ratio (F3 formulation).

Table 1.10 Drug Loading Efficiency of Dithranol Nano shampoo using different formulation

Sl.NO

Formulations

Weight of supernatant

1

F1

0.0527

2

F2

0.0499

3

F3

0.042

4

F4

0.0513

Particle Size and Surface Charge: The average particle size, zeta potential and polydispersity index of the developed nanoparticle were determined by using Litesizer 500. The particle size was found to be in the range of 380 to 500nm. The average particle size, zeta potential and polydispersity index of the developed nanoparticle were determined by using Litesizer 500. The zeta potential was found to be 31.2mV.      The F3 shows an average particle size and zeta potential of 382.2 nm and 31.2 mV respectively.

Figure 1.4 Particle size of dithranol nanoparticle

Figure 1.5 Zeta potential of dithranol particle

ATR: The ATR spectrum of pure drug, drug+polymer and optimized nanoparticle were carried out under the wavelength range of 400 to 4000cm-1 using Perkin Elmer-UATR.

Figure 1.6 ATR interpretation of dithranol nanoparticle

Figure 1.7 Combined   ATR spectrum

Thermo Gravimetric Analysis: By using Thermo Gravimetric Analysis, thermal stability of polymer+drug and nanoparticle are measured with the help of STA6000.

Sem: The Scanning Electron Microscopy was performed by using JSM-IT710HR. The SEM image was disclosed, the F3 nanoparticle was spherical in shape and they have particle size of less than 10μm.

Figure 1.9 Scanning electron microscope image of NPs

XRD: The XRD was performed using Philips PAN analytical expert PRO X-ray diffractometer 1780. In order to evaluate that the changes in the crystalline nature of the dithranol.

Figure No. 1.10 X-Ray Diffraction of Nanoshampoo

CONCLUSION

Dithranol nanoparticle was formulated by changing the concentration of chitosan. Span 80 was used as a surfactant for the preparation of nanoparticle. The prepared nanoparticle was incorporated into shampoo base. All formulations showed good homogeneity with absence of lumps and greasiness and within the range of skin pH (2.32-5.62). The maximum drug content was shown by F3 82.7%.  Zeta potential, SEM, DLS studies are done for formulations to evaluate the characteristics of nanoparticles. In-vitro permeation studies are done by using Franz diffusion cells on pig ear skin. Histopathology studies of the pig ear skin before and after the study was performed by using Eosin stain and the results shows considerable changes in the stratum corneum layer. The size range of nanoparticle may in the range of 3.50-500 nm which shows better anti-psoriatic activity than conventional. The 350 nm size suitable for trans follicular delivery, so that the nanoparticle was entrapped in the hair follicle and further release of drug happens and the nano shampoo was non staining in nature so that the patient compliance can be improved which was one of the major reasons for patient incompliance.

REFERENCES

  1. Venus M, Waterman J, McNab I. Basic physiology of the skin. Surgery (Oxford). 2010 Oct 1;28(10):469-72.
  2. Schommer NN, Gallo RL. Structure and function of the human skin microbiome. Trends in microbiology. 2013 Dec 1;21(12):660-8.
  3. Lowes MA, Bowcock AM, Krueger JG. Pathogenesis and therapy of psoriasis. Nature. 2007 Feb 22;445(7130):866-73.
  4. Ogawa E, Sato Y, Minagawa A, Okuyama R. Pathogenesis of psoriasis and development of treatment. The Journal of dermatology. 2018 Mar;45(3):264-72.
  5. Hirlekar RS, Patel PD, Dand N, Kadam VJ. Drug loaded erythrocytes: as novel drug delivery system. Current pharmaceutical design. 2008 Jan 1;14(1):63-70.
  6. Modena MM, Rühle B, Burg TP, Wuttke S. Nanoparticle characterization: what to measure? Advanced Materials. 2019 Aug;31(32):1901556
  7. Titus D, Samuel EJ, Roopan SM. Nanoparticle characterization techniques. In Green synthesis, characterization and applications of nanoparticles 2019 Jan 1 (pp. 303-319). Elsevier.
  8. Klein K, Palefsky I. Shampoo formulation. Handbook for Cleaning/Decontamination of Surfaces. 2007 Jan 1;1:277-304.
  9. Sravanthi K, Kavitha N, Sowmya K, Naazneen S, Vaishnavi U, Anil C. A Review on Formulation and Evaluation of Herbal Anti-Dandruff Shampoo. International Journal of Pharmaceutical Research and Applications. 2021;3(6):1300-11.
  10. Schaefer H, Schalla W, Shroot B. Anthralin—facts, trends and unresolved problems. Neue Entwicklungen in der Dermatologie. 1984:82-91.
  11. Greaves MW, Weinstein GD. Treatment of psoriasis. New England Journal of Medicine. 1995 Mar 2;332(9):581-9.
  12. Weigle N, McBane S. Psoriasis. American family physician. 2013 May 1;87(9):626.
  13. Rendon A, Schäkel K. Psoriasis pathogenesis and treatment. International journal of molecular sciences. 2019 Mar 23;20(6):1475.
  14. Gudjonsson JE, Elder JT. Psoriasis: epidemiology. Clinics in dermatology. 2007 Nov 1;25(6):535-46.
  15. Naldi L. Epidemiology of psoriasis. Current Drug Targets-Inflammation & Allergy. 2004 Jun 1;3(2):121-8.
  16. Menter A, Griffiths CE. Current and future management of psoriasis. The Lancet. 2007 Jul 21;370(9583):272-84.
  17. De Rie MA, Goedkoop AY, Bos JD. Overview of psoriasis. Dermatologic therapy. 2004 Oct;17(5):341-9.
  18. Pal SL, Jana U, Manna PK, Mohanta GP, Manavalan R. Nanoparticle: An overview of preparation and characterization. Journal of applied pharmaceutical science. 2011 Aug 30(Issue):228-34.
  19. Castro KC, Costa JM, Campos MG. Drug-loaded polymeric nanoparticles: a review. International Journal of Polymeric Materials and Polymeric Biomaterials. 2022 Jan 2;71(1):1-3.
  20. Murthy SK. Nanoparticles in modern medicine: state of the art and future challenges. International journal of nanomedicine. 2007 Dec 1;2(2):129-41.
  21. Wilson B, Samanta MK, Santhi K, Kumar KS, Ramasamy M, Suresh B. Chitosan nanoparticles as a new delivery system for the anti-Alzheimer drug tacrine. Nanomedicine: Nanotechnology, Biology and Medicine. 2010 Feb 1;6(1):144-52.
  22. Rampino A, Borgogna M, Blasi P, Bellich B, Cesàro A. Chitosan nanoparticles: Preparation, size evolution and stability. International journal of pharmaceutics. 2013 Oct 15;455(1-2):219-28.
  23. Mulfinger L, Solomon SD, Bahadory M, Jeyarajasingam AV, Rutkowsky SA, Boritz C. Synthesis and study of silver nanoparticles. Journal of chemical education. 2007 Feb;84(2):322.
  24. Hasan S. A review on nanoparticles: their synthesis and types. Res. J. Recent Sci. 2015; 2277:2502.
  25. Kreyling WG, Semmler-Behnke M, Möller W. Health implications of nanoparticles. Journal of Nanoparticle Research. 2006 Oct;8:543-62.

Reference

  1. Venus M, Waterman J, McNab I. Basic physiology of the skin. Surgery (Oxford). 2010 Oct 1;28(10):469-72.
  2. Schommer NN, Gallo RL. Structure and function of the human skin microbiome. Trends in microbiology. 2013 Dec 1;21(12):660-8.
  3. Lowes MA, Bowcock AM, Krueger JG. Pathogenesis and therapy of psoriasis. Nature. 2007 Feb 22;445(7130):866-73.
  4. Ogawa E, Sato Y, Minagawa A, Okuyama R. Pathogenesis of psoriasis and development of treatment. The Journal of dermatology. 2018 Mar;45(3):264-72.
  5. Hirlekar RS, Patel PD, Dand N, Kadam VJ. Drug loaded erythrocytes: as novel drug delivery system. Current pharmaceutical design. 2008 Jan 1;14(1):63-70.
  6. Modena MM, Rühle B, Burg TP, Wuttke S. Nanoparticle characterization: what to measure? Advanced Materials. 2019 Aug;31(32):1901556
  7. Titus D, Samuel EJ, Roopan SM. Nanoparticle characterization techniques. In Green synthesis, characterization and applications of nanoparticles 2019 Jan 1 (pp. 303-319). Elsevier.
  8. Klein K, Palefsky I. Shampoo formulation. Handbook for Cleaning/Decontamination of Surfaces. 2007 Jan 1;1:277-304.
  9. Sravanthi K, Kavitha N, Sowmya K, Naazneen S, Vaishnavi U, Anil C. A Review on Formulation and Evaluation of Herbal Anti-Dandruff Shampoo. International Journal of Pharmaceutical Research and Applications. 2021;3(6):1300-11.
  10. Schaefer H, Schalla W, Shroot B. Anthralin—facts, trends and unresolved problems. Neue Entwicklungen in der Dermatologie. 1984:82-91.
  11. Greaves MW, Weinstein GD. Treatment of psoriasis. New England Journal of Medicine. 1995 Mar 2;332(9):581-9.
  12. Weigle N, McBane S. Psoriasis. American family physician. 2013 May 1;87(9):626.
  13. Rendon A, Schäkel K. Psoriasis pathogenesis and treatment. International journal of molecular sciences. 2019 Mar 23;20(6):1475.
  14. Gudjonsson JE, Elder JT. Psoriasis: epidemiology. Clinics in dermatology. 2007 Nov 1;25(6):535-46.
  15. Naldi L. Epidemiology of psoriasis. Current Drug Targets-Inflammation & Allergy. 2004 Jun 1;3(2):121-8.
  16. Menter A, Griffiths CE. Current and future management of psoriasis. The Lancet. 2007 Jul 21;370(9583):272-84.
  17. De Rie MA, Goedkoop AY, Bos JD. Overview of psoriasis. Dermatologic therapy. 2004 Oct;17(5):341-9.
  18. Pal SL, Jana U, Manna PK, Mohanta GP, Manavalan R. Nanoparticle: An overview of preparation and characterization. Journal of applied pharmaceutical science. 2011 Aug 30(Issue):228-34.
  19. Castro KC, Costa JM, Campos MG. Drug-loaded polymeric nanoparticles: a review. International Journal of Polymeric Materials and Polymeric Biomaterials. 2022 Jan 2;71(1):1-3.
  20. Murthy SK. Nanoparticles in modern medicine: state of the art and future challenges. International journal of nanomedicine. 2007 Dec 1;2(2):129-41.
  21. Wilson B, Samanta MK, Santhi K, Kumar KS, Ramasamy M, Suresh B. Chitosan nanoparticles as a new delivery system for the anti-Alzheimer drug tacrine. Nanomedicine: Nanotechnology, Biology and Medicine. 2010 Feb 1;6(1):144-52.
  22. Rampino A, Borgogna M, Blasi P, Bellich B, Cesàro A. Chitosan nanoparticles: Preparation, size evolution and stability. International journal of pharmaceutics. 2013 Oct 15;455(1-2):219-28.
  23. Mulfinger L, Solomon SD, Bahadory M, Jeyarajasingam AV, Rutkowsky SA, Boritz C. Synthesis and study of silver nanoparticles. Journal of chemical education. 2007 Feb;84(2):322.
  24. Hasan S. A review on nanoparticles: their synthesis and types. Res. J. Recent Sci. 2015; 2277:2502.
  25. Kreyling WG, Semmler-Behnke M, Möller W. Health implications of nanoparticles. Journal of Nanoparticle Research. 2006 Oct;8:543-62.

Photo
Aadi Sathyan
Corresponding author

Research Scholar , Shri JJT University, Rajasthan.

Photo
Dr. Rakesh Kumar Jat
Co-author

Department of Pharmaceutical Sciences, Shri JJT University Rajasthan.

Photo
Dr. Lal Prasanth M. L.
Co-author

Department of Pharmaceutical Chemistry, Dr. Moopen’s College of Pharmacy,Wayanad,Kerala.

Aadi Sathyan*, Dr. Rakesh Kumar Jat, Dr. Lal Prasanth M. L., Formulation and Evaluation of Anthralin Nano particle loaded shampoo for Alopecia areata, Int. J. of Pharm. Sci., 2025, Vol 3, Issue 9, 1305-1314 https://doi.org/10.5281/zenodo.17104733

More related articles
Formulation And Evaluation of Polyherbal Anti- Mic...
Neha Mundhe, Sonali Kamble, Snehal Jogdand, Madhavi Shelke, Vaish...
A Review Article on Artificial Intelligence and Ma...
Amarlapudi Elwin , Bhupelly Gremya, Tennati Devayani, Devara Divy...
Tinospora Cordifolia – As An Anticancer Agent: ...
Arpita R. Pawar, Ashwini T. Chougule, Jaya R. Kamble, Pritam Salo...
Review Of Monkeypox Virus :Symptoms ,Pathogenesis ,Diagnosis And Treatment...
Pratiksha A. Udawant, Sabafarin Shaikh, Khare Komal, Mayur S. Bhosle, Sushmita Chavan, ...
Exploring The Potentials Of Colebrookea Oppositifolia For Treatement Of Mouth Ul...
, Rahul Sharma, Chinu Kumari, Dev Prakash Dahiya, Nikhil Rana, Kanika, ...
More related articles
Formulation And Evaluation of Polyherbal Anti- Microbial Hair Gel...
Neha Mundhe, Sonali Kamble, Snehal Jogdand, Madhavi Shelke, Vaishnavi Mugale, ...
A Review Article on Artificial Intelligence and Machine Learning in Revolutioniz...
Amarlapudi Elwin , Bhupelly Gremya, Tennati Devayani, Devara Divya, Pittala Akhil, ...
Tinospora Cordifolia – As An Anticancer Agent: Recent And Advance Study...
Arpita R. Pawar, Ashwini T. Chougule, Jaya R. Kamble, Pritam Salokhe, Nilesh B. Chougule, ...
Formulation And Evaluation of Polyherbal Anti- Microbial Hair Gel...
Neha Mundhe, Sonali Kamble, Snehal Jogdand, Madhavi Shelke, Vaishnavi Mugale, ...
A Review Article on Artificial Intelligence and Machine Learning in Revolutioniz...
Amarlapudi Elwin , Bhupelly Gremya, Tennati Devayani, Devara Divya, Pittala Akhil, ...
Tinospora Cordifolia – As An Anticancer Agent: Recent And Advance Study...
Arpita R. Pawar, Ashwini T. Chougule, Jaya R. Kamble, Pritam Salokhe, Nilesh B. Chougule, ...